Results 261 to 270 of about 28,823 (297)
Some of the next articles are maybe not open access.
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Current Cardiology Reports, 2013It is well known that patients with type 2 diabetes mellitus (T2DM) are at increased risk of cardiovascular (CV) disease. Elevated plasma glucose levels that independently lead to increased cardiovascular risk, combined with associated co-morbidities such as obesity, hypertension, and dyslipidemia, further contribute to the development of CV ...
B, Solun, D, Marcoviciu, D, Dicker
openaire +2 more sources
Dipeptidyl peptidase‐4 inhibitors and angioedema: a class effect?
Diabetic Medicine, 2013AbstractBackgroundDipeptidyl peptidase‐4 (DPP‐4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs.Case reportWe report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP‐4 inhibitor, alogliptin.DiscussionOur case
Y, Saisho, H, Itoh
openaire +2 more sources
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Clinical Pharmacokinetics, 2012Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying ...
Larry K, Golightly +2 more
openaire +2 more sources
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species.
Juan M, Betancort +12 more
openaire +2 more sources
Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin
Postgraduate Medicine, 2013Dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as new options in the management of type 2 diabetes mellitus, demonstrating meaningful antihyperglycemic effects and good tolerability profiles. Glycemic control is improved by preventing the DPP-4-mediated degradation of incretin hormones, with a resulting increase in insulin secretion and ...
openaire +2 more sources
Inhibitors of Dipeptidyl Peptidase 4
2005Stephen L. Gwaltney, Jeffrey A. Stafford
openaire +1 more source
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Iis Inayati Rakhmat +2 more
exaly
Iis Inayati Rakhmat +2 more
exaly